Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 35

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 35
---
.

<div align='center'>S-19</div>

### PLAN OF DISTRIBUTION
We previously entered into an equity distribution agreement, dated February 28, 2022 (the “prior equity distribution agreement”), under which we could issue and sell from time to time an aggregate of up to $400.0 million of shares of common stock through Goldman Sachs & Co. LLC ,Leerink Partners LLC, and Cantor Fitzgerald & Co. As of the date of this prospectus, $400.0 million of shares of common stock remained available for sale under the prior equity distribution agreement. No sales will be made pursuant to the prior equity distribution agreement subsequent to the date of this prospectus supplement.

We have entered into an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC as our sales agents, under which we may offer and sell from time to time shares of our common stock having an aggregate offering price of up to $400.0 million. The sales agents may act as agents on our behalf or purchase shares of common stock as principal.

Sales, if any, of shares of common stock under the equity distribution agreement may be made in ordinary brokers’ transactions, to or through a market maker, on or through the Nasdaq Global Select Market or any other market venue where the securities may be traded, in the over-the-counter market, in privately negotiated transactions, or through a combination of any such methods of sale. The sales agents may also sell our common shares by any other method permitted by law.

The securities may be sold at market prices prevailing at the time of sale, at prices related to such prevailing market prices, or at negotiated prices.

We will designate the maximum amount of shares of common stock to be sold through the sales agents on a daily basis or otherwise as we and the sales agents agree and the minimum price per share at which such common stock may be sold. Subject to the terms and conditions of the equity distribution agreement, the sales agents will use their commercially reasonable efforts consistent with their normal sales and trading practices to sell on our behalf all of the designated common stock. We may instruct the sales agents not to sell any shares if the sales cannot be effected at or above the price designated by us in any such instruction. We or any sales agent, with respect to itself only, may suspend the offering of our common stock by notifying the other party. The offering of the shares by the sales agents is subject to receipt and acceptance and subject to the sales agents’ right to reject any order in whole or in part